A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Phase 3 Recruiting
440 enrolled
A Study of Daratumumab
Phase 3 Recruiting
500 enrolled
CERVINO
Phase 3 Recruiting
380 enrolled
Iber-KDd
Phase 2 Recruiting
30 enrolled
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Phase 1/2 Recruiting
246 enrolled
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Phase 1/2 Recruiting
66 enrolled
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Phase 1/2 Recruiting
440 enrolled
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Phase 1 Recruiting
125 enrolled
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Phase 3 Recruiting
492 enrolled
MagnetisMM-20
Phase 1 Recruiting
90 enrolled
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Phase 1 Recruiting
317 enrolled
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Phase 1/2 Recruiting
70 enrolled
STOMP
Phase 1/2 Recruiting
300 enrolled
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Phase 2 Recruiting
83 enrolled
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Phase 2 Recruiting
43 enrolled
Home Treatment With Carfilzomib in Patients With Multiple Myeloma
Recruiting
12 enrolled
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
Phase 4 Recruiting
59 enrolled
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Recruiting
15 enrolled
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Phase 2/3 Recruiting
176 enrolled
KPD Consolidation After ASCT in NDMM Patients
Phase 2/3 Recruiting
202 enrolled
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
Phase 1/2 Recruiting
60 enrolled